RNTX Stock — Rein Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.80

Market cap

$69.0M

Cash

$40.6M

Enterprise value

$28.4M

Balance sheet

Cash	$40.6M
Debt	$0.0M
Net cash	$40.6M
Enterprise value	$28.4M
Basic shares	85.8M shares
Fully diluted shares	90.1M shares
Fully diluted market cap	$72.1M
Cash per share	$0.47

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RNTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 11 - Dec 23	LTI-03	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LTI-03

Phase 2 · Active Modality: peptide (caveolin-1 scaffolding-protein-derived; inhaled dry powder)

Partnerships UT System/UTHSCT: exclusive license covering LTI-03 (royalty-bearing; milestone/diligent-commercialization terms)

Indications

Idiopathic pulmonary fibrosis (IPF) (Phase 2)

Catalysts

— Q4 2026

Status note RENEW trial: Phase 2 multi-center, randomized, double-blind, placebo-controlled; first patient dosed Mar 2026; screening began May 2025. EMA orphan drug designation Jan 2026.

LTI-01

Phase 2 · Active Modality: proenzyme

Target plasminogen

Partnerships UT System/UTHSCT: exclusive license covering LTI-01

Indications

Loculated pleural effusion (Phase 2)

Status note Phase 2a dose-ranging and Phase 1b completed. Paused indefinitely while resources are prioritized toward LTI-03; resumption timing uncertain.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LTI-03
Lead indication	Idiopathic Pulmonary Fibrosis (IPF)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06968845	Phase 2	Recruiting	Sponsor	Rein Therapeutics	—	Idiopathic Pulmonary Fibrosis (IPF)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Rein Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	4,500,000	+4,500,000	0.22%	2026-08-14
Ikarian Capital	2,950,000	+2,950,000	0.50%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

RNTX — Rein Therapeutics Inc.